Siemens Healthineers launches capillary testing menu on Atellica analyzers
September 2026—Siemens Healthineers has launched capillary testing on the Atellica CH, IM, and CI analyzers after receiving the CE mark for 24 capillary blood testing claims.
Webinars and Sponsored Roundtables — Register Now
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
PathVisions26: Connecting Innovation with Purpose
September 2026—The Digital Pathology Association’s annual meeting, Pathology Visions 2026, is taking place October 16–18 in San Diego. Join the Digital Pathology Association for three days of education, collaboration, and the latest advancements in digital pathology and AI. Connect with more than 1,000 pathologists, researchers, laboratory leaders, health care professionals, and industry innovators who are driving the next era of precision medicine.
Horiba launches Yumivet VH2500 hematology analyzer
September 2026—Horiba has launched Yumivet, its new veterinary diagnostics brand, and introduced the Yumivet VH2500 hematology analyzer.
ARUP launches Clarispect myeloma MRD assay
September 2026—ARUP Laboratories has launched ARUP Clarispect Multiple Myeloma MRD by Spectral Flow Cytometry.
Atellica testosterone assay gets CDC HoSt-TT certification
September 2026—Siemens Healthineers’ Atellica IM Testosterone II assay has achieved certification through the Centers for Disease Control and Prevention hormone standardization program for total testosterone, confirming that the Atellica IM TSTII immunoassay’s test results are equivalent to high-performance liquid chromatography coupled with tandem mass spectrometry.
BD Bactec FXI culture system gets FDA clearance
September 2026—Waters Corp. announced that the BD Bactec FXI culture system has received FDA 510(k) clearance.
RMT achieves SOC 2 type 2 certification
September 2026—Remote Medical Technologies has achieved SOC 2 type 2 certification. The certification verifies that the company’s controls related to security, availability, and confidentiality are properly designed and operate effectively over an extended time.
Pillar, LC-SCRUM-Asia, LSI Medience partner on liquid biopsy screening
September 2026—Pillar Biosciences, LC-SCRUM-Asia, and LSI Medience Corp. are collaborating to support the genomic screening of blood-based samples from patients with lung cancer as part of the LC-SCRUM-Asia project in Japan. The participating organizations plan to begin testing following approval of a revision to the LC-SCRUM-Asia project protocol.
MRC Holland launches digitalMLPA assay for DMD
September 2026—MRC Holland has launched its NXtec D008 DMD, a digitalMLPA assay designed for the detection of copy number variations linked to Duchenne and Becker muscular dystrophies.
Liaison Nes group A strep assay gets clearance, CLIA waiver
September 2026—Diasorin has received 510(k) clearance and CLIA waiver from the U.S. Food and Drug Administration for its group A streptococcus assay, for use on the Liaison Nes point-of-care molecular diagnostics platform.